Scotland has approved its first CLDN18.2-targeted therapy for advanced gastric and GEJ cancer, expanding options for patients ...

Proton pump inhibitors are among the most commonly prescribed medications worldwide, but concerns about a possible link to stomach cancer have lingered for decades. Proton pump inhibitors (PPIs) are a ...

Scientists at Duke-NUS Medical School and the National University Health System (NUHS), together with an international team ...

Genetic mutations, oxidative stress, smoking, oral bacteria, and age-related blood mutations have been identified as early ...

Scientists at Duke-NUS Medical School and the National University Health System (NUHS), together with an international team of researchers, have uncovered a complex interplay of factors that increase ...

Astellas Pharma has announced that the Scottish Medicines Consortium has accepted zolbetuximab for use on the NHS in Scotland ...

Ibuprofen may be doing more than easing aches and pains—it could also help reduce the risk of some cancers. Studies have ...

He's lost his father, a brother, aunts, uncles and extended family members to cancer — many of them in their 30s and 40s.

The Scottish Medicines Consortium has approved zolbetuximab – to be used together with chemotherapy – to treat those with ...

Explore how claudin-18.2 can transform cancer treatment for gastric and pancreatic tumours using targeted radiotherapy.

Why do some tumors spread while others remain localized? The mechanisms governing the metastatic potential of tumor cells ...

A new gene therapy for people who can have a stem cell transplant but do not have a suitable donor has been approved.